Trinity biotech announces entry into a letter of intent with bayer for a joint partnership to launch a cgm biosensor device in china and india

Dublin, ireland, jan. 31, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib) (the “company”) today announced that it has entered into a non-binding letter of intent with bayer for the launch of a continuous glucose monitoring (“cgm”) biosensor device in china and india. this letter of intent is related to the company's recently announced  acquisition of the cgm assets of waveform technologies, inc.
TRIB Ratings Summary
TRIB Quant Ranking